Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amgen
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Men and women with ages between 18 and 65 years old, inclusive, at time of signing consent
Body mass index (BMI) between greater than or equal to 30.0 kg/m\^2 and less than or equal to 40.0 kg/m\^2 at screening
Except for obesity, otherwise healthy or medically stable per protocol
Have a stable body weight defined as less than 5 kg self-reported change during the previous 8 weeks prior to screening
Stable on liraglutide, depending on cohort
You may not be if
History or clinical evidence of diabetes
Inadequate organ function at screening
Currently receiving treatment in another investigational device or drug study
Women who are pregnant/lactating/breastfeeding or who plan to become pregnant/breastfeed while on study through 5 months after receiving the last dose of investigational product
History or evidence of a clinically significant disorder, condition or disease that would pose a risk to subject safety or interfere with the study evaluation, procedures or completion
A family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2; a personal history of non-familial medullary thyroid carcinoma; confirmed chronic pancreatitis or idiopathic acute pancreatitis, or gallbladder disease (ie, cholelithiasis or cholecystitis) not treated with cholecystectomy, for cohorts receiving liraglutide
